Submit an Article

Navigate

Submit an Article

Online ISSN: 1945-4589

Research Paper|Volume 15, Issue 17|pp. 8744–8769

Comprehensive analysis and experimental validation reveal elevated CLCN4 is a promising biomarker in endometrial cancer

Back to articleFigure 4(4 of 14)

−100%+

Figure 4.Correlation between CLCN4 expression and tumor immune subtypes. Expression of CLCN4 in TISIDB in different tumor immune subtypes. (A) BLCA. (B) BRCA. (C) COAD. (D) GBM. (E) HNSC. (F) KIRC. (G) KIRP. (H) LGG. (I) PCPG. (J) STAD. (K) TGCT. (L) THCA. (M) UCEC. (N) UVM.